EP receptor agonists and other osteogenic therapies for bone repair

Mone Zaidi, Neeha Zaidi, Li Sun

Research output: Contribution to journalReview article

Abstract

There is growing evidence that new molecules targeting either EP 2 or EP4 receptors can enhance osteogenesis when injected locally, and hence may have potential application in bone repair. This could be of particular value in enhancing the healing of fractures, and the bridging of surgical osteotomy gaps in children with growth defects. In addition, EP 4 agonists show promise in the prevention and restoration of ovariectomy-induced bone loss. Phase II and III trials with these compounds should allow their evaluation for use in humans, with the understanding that side effects due to the ubiquitous and overlapping distribution of EP receptors may pose a therapeutic challenge.

Original languageEnglish (US)
Pages (from-to)833-837
Number of pages5
JournalDrugs of the Future
Volume32
Issue number9
DOIs
StatePublished - Sep 1 2007
Externally publishedYes

Fingerprint

Bone and Bones
Fracture Healing
Ovariectomy
Osteotomy
Osteogenesis
Therapeutics
Growth

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

EP receptor agonists and other osteogenic therapies for bone repair. / Zaidi, Mone; Zaidi, Neeha; Sun, Li.

In: Drugs of the Future, Vol. 32, No. 9, 01.09.2007, p. 833-837.

Research output: Contribution to journalReview article

Zaidi, Mone ; Zaidi, Neeha ; Sun, Li. / EP receptor agonists and other osteogenic therapies for bone repair. In: Drugs of the Future. 2007 ; Vol. 32, No. 9. pp. 833-837.
@article{509a512a6ac549c2aaaf01eae5e1f86a,
title = "EP receptor agonists and other osteogenic therapies for bone repair",
abstract = "There is growing evidence that new molecules targeting either EP 2 or EP4 receptors can enhance osteogenesis when injected locally, and hence may have potential application in bone repair. This could be of particular value in enhancing the healing of fractures, and the bridging of surgical osteotomy gaps in children with growth defects. In addition, EP 4 agonists show promise in the prevention and restoration of ovariectomy-induced bone loss. Phase II and III trials with these compounds should allow their evaluation for use in humans, with the understanding that side effects due to the ubiquitous and overlapping distribution of EP receptors may pose a therapeutic challenge.",
author = "Mone Zaidi and Neeha Zaidi and Li Sun",
year = "2007",
month = "9",
day = "1",
doi = "10.1358/dof.2007.032.09.1124489",
language = "English (US)",
volume = "32",
pages = "833--837",
journal = "Drugs of the Future",
issn = "0377-8282",
publisher = "Prous Science",
number = "9",

}

TY - JOUR

T1 - EP receptor agonists and other osteogenic therapies for bone repair

AU - Zaidi, Mone

AU - Zaidi, Neeha

AU - Sun, Li

PY - 2007/9/1

Y1 - 2007/9/1

N2 - There is growing evidence that new molecules targeting either EP 2 or EP4 receptors can enhance osteogenesis when injected locally, and hence may have potential application in bone repair. This could be of particular value in enhancing the healing of fractures, and the bridging of surgical osteotomy gaps in children with growth defects. In addition, EP 4 agonists show promise in the prevention and restoration of ovariectomy-induced bone loss. Phase II and III trials with these compounds should allow their evaluation for use in humans, with the understanding that side effects due to the ubiquitous and overlapping distribution of EP receptors may pose a therapeutic challenge.

AB - There is growing evidence that new molecules targeting either EP 2 or EP4 receptors can enhance osteogenesis when injected locally, and hence may have potential application in bone repair. This could be of particular value in enhancing the healing of fractures, and the bridging of surgical osteotomy gaps in children with growth defects. In addition, EP 4 agonists show promise in the prevention and restoration of ovariectomy-induced bone loss. Phase II and III trials with these compounds should allow their evaluation for use in humans, with the understanding that side effects due to the ubiquitous and overlapping distribution of EP receptors may pose a therapeutic challenge.

UR - http://www.scopus.com/inward/record.url?scp=36349019785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36349019785&partnerID=8YFLogxK

U2 - 10.1358/dof.2007.032.09.1124489

DO - 10.1358/dof.2007.032.09.1124489

M3 - Review article

AN - SCOPUS:36349019785

VL - 32

SP - 833

EP - 837

JO - Drugs of the Future

JF - Drugs of the Future

SN - 0377-8282

IS - 9

ER -